Filter By Category
Archives
Share on -
DATOPOTAMAB DERUXTECAN
Generic Name: DATOPOTAMAB DERUXTECAN
ABSTRACT -
Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate composed of the datopotamab antibody linked to a topoisomerase-I inhibitor payload. The structural image is therefore presented as an ADC schematic rather than as a single small molecule.
DOSAGE -
Use only according to oncology product labeling or clinical protocol; dosing and premedication are regimen-specific.
SIDE EEFECTS -
- Infusion-related reactions
- Nausea and decreased appetite
- Myelosuppression
- Mucositis or stomatitis
- Interstitial lung disease/pneumonitis risk (class-related)
ALLERGIC REACTIONS -
- (These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or urticaria
- Bronchospasm
- Facial swelling
- Anaphylaxis
DRUG INTERACTIONS-
- Concomitant myelosuppressive therapies may increase toxicity
- Payload-related interactions should be considered
- Follow product-specific guidance for supportive care and monitoring
PREAUTONS–
- Monitor complete blood counts and pulmonary symptoms
- Assess liver function and infusion tolerance
- Use expert oncology supervision
WARNINGS –
- Severe or fatal pneumonitis/ILD may occur with some ADCs
- Serious infusion and hypersensitivity reactions are possible
- Fetal harm may occur; follow contraception guidance
Share on -
. Developed by